文献速递腹部泌尿生殖CTMR

评估有癌症病史患者肾上腺结节的恶性率:与肾上腺转移相关的因素

Assessing the malignancy rate of adrenal nodules in patients with a history of cancer: factors associated with adrenal metastases.
PubMed 文献 · Abdom Radiol (NY) · 2025-10-09

本回顾性研究纳入2010年1月1日至2020年12月31日期间有肾上腺外恶性肿瘤病史且肾上腺结节≥1 cm的420例患者,总体肾上腺结节转移率为15.7%(66/420)。有肾上腺外转移性疾病者肾上腺结节转移率高于孤立性肾上腺结节者(24.5% vs. 10.8%,p≤0.001)。黑色素瘤(50%)和肺癌(32%)患者肾上腺转移最常见,结节大小2-4 cm(OR 1.98)和>4 cm(OR 3.25)与转移风险增加相关。

要点

  • 有癌症病史患者中,孤立性肾上腺结节近90%为良性。
  • 合并肾上腺外转移性疾病者肾上腺结节转移率显著高于孤立性结节者(24.5% vs. 10.8%,p≤0.001)。
  • 肺癌、黑色素瘤病史或结节≥2 cm显著增加肾上腺转移风险。

核心结论

  • 在有任意类型恶性肿瘤病史的患者队列中,近90%的孤立性肾上腺结节为良性,但肺癌、黑色素瘤病史或病灶大小≥2 cm显著增加肾上腺转移风险。

研究设计与样本

  • 经机构审查委员会批准的回顾性研究,于2010年1月1日至2020年12月31日在一学术健康系统进行,通过癌症登记数据和自然语言处理识别有肾上腺外恶性肿瘤病史且接受增强腹部CT或MRI检查、肾上腺结节≥1 cm的患者,最终纳入420例(女性219例,平均年龄71.4岁,标准差11.1),参考标准为病理(可得时)或影像随访≥1年。

诊断标准与关键数值

  • 总体转移性肾上腺结节率为15.7%(66/420);有肾上腺外转移性疾病者转移率24.5%(37/151),孤立性肾上腺结节者10.8%(29/269),p≤0.001;黑色素瘤患者转移率50%(10/20),肺癌患者32%(24/75);结节大小2-4 cm的OR为1.98,>4 cm的OR为3.25;在孤立性肾上腺结节患者中,肺癌OR 10.80、黑色素瘤OR 32.91、结节2-4 cm OR 5.14、>4 cm OR 9.69。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To determine malignancy rate of adrenal nodules in patients with a history of cancer and identify factors predictive of adrenal metastases.

METHODS: This Institutional Review Board-approved, retrospective study was performed 1/1/2010-12/31/2020 at an academic health system. Cancer registry data and natural language processing identified patients with a history of extra-adrenal malignancy who had undergone contrast-enhanced abdominal CT or MRI and had adrenal nodules ≥ 1 cm. A power calculation based on previously published prevalence of malignancy in adrenal nodules determined the minimum number of patients. The reference standard used for diagnosis was pathology when available, or imaging follow-up ≥ 1 year. Cancer type, presence/absence of extra-adrenal metastatic disease on index scan, and size of the adrenal nodule were extracted from the electronic health record. These factors were correlated with adrenal nodule outcome (benign or metastatic) using univariate and multivariable logistic regression analyses.

RESULTS: The cohort included 420 patients (219 female; mean age 71.4 years [standard deviation 11.1]). Overall metastatic adrenal nodule rate was 15.7% (66/420). Patients with extra-adrenal metastatic disease were more likely to have metastatic adrenal nodules compared to those with an isolated adrenal nodule (24.5% [37/151] vs. 10.8% [29/269]; p ≤ 0.001). Adrenal metastases were most common in patients with melanoma (50%, 10/20) and lung cancer (32%, 24/75). Metastatic rate increased with nodule size 2-4 cm (Odds Ratio [OR] 1.98) and > 4 cm (OR 3.25). In patients with an isolated adrenal nodule, primary malignancy (lung cancer: OR 10.80; melanoma: OR 32.91) and size (2-4 cm: OR 5.14, > 4 cm: OR 9.69) were associated with increased risk of metastases.

CONCLUSION: In a cohort of patients with a history of any type of malignancy, almost 90% of isolated adrenal nodules were benign. However, a history of lung cancer, melanoma, or lesion size ≥ 2 cm significantly increased the risk of adrenal metastases.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Satani AA, Lacson R, Silverman SG, et al. Assessing the malignancy rate of adrenal nodules in patients with a history of cancer: factors associated with adrenal metastases. Abdom Radiol (NY). 2025. PMID: 41065829. doi:10.1007/s00261-025-05221-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。